Orexo has been granted a patent for a solid pharmaceutical composition for nasal delivery of an opioid antagonist. The formulation includes naloxone and a carrier like disaccharides and dextrins, spray-dried into a powder for use in single-use nasal applicators. The composition is stable and effective in treating opioid overdose. GlobalData’s report on Orexo gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Orexo AB - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Orexo, Cancer treatment biomarkers was a key innovation area identified from patents. Orexo's grant share as of January 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for solid pharmaceutical composition for nasal naloxone delivery

Source: United States Patent and Trademark Office (USPTO). Credit: Orexo AB

A recently granted patent (Publication Number: US11883392B2) discloses a solid pharmaceutical composition in the form of a spray-dried powder designed for nasal delivery of naloxone or its pharmaceutically-acceptable salt. The composition, free of water, includes a combination of a disaccharide (such as maltitol, trehalose, or lactose) and a dextrin as carrier materials. The patent highlights the stability of the composition, with less than 15% chemical degradation of naloxone after storage for 3 months at 75% relative humidity and 40°C. Additionally, the particle size distribution, glass transition temperature, and specific ingredients like a-D-lactose monohydrate and maltodextrin play crucial roles in the formulation.

Moreover, the patent covers a method for manufacturing the pharmaceutical composition, involving mixing naloxone with carrier materials in a volatile solvent and spray-drying the mixture to form the desired powder. It also includes details on a nasal applicator device suitable for delivering the composition to the nose, emphasizing the importance of packaging within containers that prevent the ingress of atmospheric water under specific storage conditions. The patent further extends to methods of treating opioid overdose using the disclosed composition and applicator device, showcasing a comprehensive approach to addressing this critical medical need with innovative pharmaceutical technology.

To know more about GlobalData’s detailed insights on Orexo, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies